Achieve life sciences announces positive outcome of second data safety monitoring committee review for the orca-ol clinical trial

No safety concerns identified by dsmc in the orca-ol long-term exposure trial achieve reiterates planned cytisinicline nda submission in q2 2025 seattle and vancouver, british columbia, feb. 10, 2025 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the data safety monitoring committee (dsmc) has recently completed its second independent review of the ongoing orca-ol trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen in individuals who smoke cigarettes or vape nicotine. following this second comprehensive review of available safety data, the dsmc stated that it did not identify any unexpected treatment-related adverse events and that the participants' adherence to their cytisinicline medication was excellent.
ACHV Ratings Summary
ACHV Quant Ranking